Literature DB >> 666609

Subacute demyelinating polyneuropathy responding to corticosteroid treatment.

S J Oh.   

Abstract

Ten patients with subacute demyelinating neuropathy responded satisfactorily to corticosteroid treatment. The most prominent features in these cases were (1) subacute progression of diffuse polyneuropathy over weeks and months, (2) high spinal fluid protein level, (3) marked nerve conduction abnormalities, and (4) high rate of relapse. The sural nerve biopsy specimen showed "demyelinating neuropathy." This subacute demyelination neuropathy appears to be a distinct and clinically identifiable entity in which corticosteroid treatment is indicated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 666609     DOI: 10.1001/archneur.1978.00500320029007

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  6 in total

1.  Electrophysiological profile in arsenic neuropathy.

Authors:  S J Oh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

2.  Treatment of peripheral neuropathies.

Authors:  M Hallett; D Tandon; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

3.  Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.

Authors:  R Korinthenberg; J S Mönting
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791

4.  "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy.

Authors:  S J Oh; J L Joy; R Kuruoglu
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

5.  Idiopathic inflammatory polyradiculoneuropathy: evaluation of clinical and laboratory data and therapeutic considerations.

Authors:  G Valli; L Ferini Strambi; E Nobile Orazio; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1983-04

6.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.